KemPharm, Inc (KMPH) is a leading biotechnology business based in the US. On 18 June KemPharm shares plunged 9.95% to a closing position of $13.93. However, over the last 12 months, KemPharm's share price has risen by a staggering 386.67% from $3 (accounting for the 28 December 2020 split). KemPharm is listed on the NASDAQ and employs 22 staff. All prices are listed in US Dollars.
Since the stock market crash that started in February 2020, KemPharm's share price has had significant positive movement.
Its last market close was $10.24, which is 45.12% up on its pre-crash value of $5.62 (accounting for the 28 December 2020 split) and 255.56% up on the lowest point reached during the March 2020 crash when the shares fell as low as $2.88 (accounting for the 28 December 2020 split).
If you had bought $1,000 worth of KemPharm shares at the start of February 2020, those shares would have been worth $599.42 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,828.56.
|52-week range||$3.84 - $22.08|
|50-day moving average||$10.6011|
|200-day moving average||$10.311|
|Wall St. target price||$19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.729|
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 month (2021-05-20)||46.15%|
|3 months (2021-03-19)||31.29%|
|6 months (2020-12-18)||-22.01%|
|1 year (2020-06-19)||236.59%|
|2 years (2019-06-20)||-48.45%|
|3 years (2018-06-20)||-85.96%|
|5 years (2016-06-20)||-78.58%|
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
KemPharm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.4 million.
The EBITDA is a measure of a KemPharm's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
|Revenue TTM||$23.3 million|
|Operating margin TTM||21.98%|
|Gross profit TTM||$12 million|
|Return on assets TTM||6.45%|
|Return on equity TTM||-222.16%|
|Market capitalisation||$441 million|
TTM: trailing 12 months
There are currently 3.5 million KemPharm shares held short by investors – that's known as the "short interest". This figure is 3.9% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting KemPharm shares can be evaluated.
KemPharm's "short interest ratio" (SIR) is the quantity of KemPharm shares currently shorted divided by the average quantity of KemPharm shares traded daily (recently around 580723.2405892). KemPharm's SIR currently stands at 6.11. In other words for every 100,000 KemPharm shares traded daily on the market, roughly 6110 shares are currently held short.
To gain some more context, you can compare KemPharm's short interest ratio against those of similar companies.
However KemPharm's short interest can also be evaluated against the total number of KemPharm shares, or, against the total number of tradable KemPharm shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case KemPharm's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 KemPharm shares in existence, roughly 120 shares are currently held short) or 0.1445% of the tradable shares (for every 100,000 tradable KemPharm shares, roughly 145 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against KemPharm.
Find out more about how you can short KemPharm stock.
We're not expecting KemPharm to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
KemPharm's shares were split on a 1:16 basis on 28 December 2020. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.
Over the last 12 months, KemPharm's shares have ranged in value from as little as $3.84 up to $22.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 3.3587. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put KemPharm's beta into context you can compare it against those of similar companies.
This guide will show you step-by-step instructions on how to buy the TitanSwap (TITAN) token as well as a list of exchanges you can trade it on.
AMC Entertainment Shares surpassed $50 last week to be up more than 2,000% this year, replacing GameStop as Reddit investors most beloved meme stock.
We used ADAC safety testing data to compare the 10 best child car seats to buy in the UK for 2021. Compare price, weight and safety features.
20% of British adults plan to shop the Amazon Prime Day 2021 sales, according to the latest statistics from Finder’s Amazon Prime Day shopping report.
Does Apple have a back-to-school sale in the UK? Find out when the deals start and what to expect from this year’s Apple sale.
Shares in AMC Entertainment Holdings are again closing in on their all-time high. The cinema operator has jumped 111% in the past 5 sessions alone. Find out what’s going on with this “meme stock”.
See if you can get your next Secret Sales order for less with our hand-tested voucher and promo codes.
Find out the difference between a credit score and a credit report as well as what factors can bring it up and down?
This guide will show you step-by-step instructions on how to buy the SafeMoon (SAFEMOON) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Shiba Inu (SHIB) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.